Eli Lilly (LLY) and Company announced that the U.S. FDA approved a single-injection, once-monthly maintenance regimen (200 mg/2 mL) of Omvoh for subcutaneous use in adults with moderately to severely active ulcerative colitis.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly’s Latest Study on Abemaciclib: A Potential Game-Changer in Pediatric Cancer Treatment
- Eli Lilly’s Orforglipron Study: A Potential Game-Changer in Diabetes Treatment
- Eli Lilly Withdraws Key Obesity and Diabetes Study: Market Implications
- Eli Lilly’s Obesity Study: A Potential Game-Changer in Calorie Management
- Eli Lilly’s Orforglipron Study: A New Hope for Type 2 Diabetes Management